Lymphokine-activated killer cell (LAK cell)

Lymphokine-activated killer cells are not a single molecular target or receptor but rather a **heterogeneous population of white blood cells**—primarily natural killer (NK) cells, NK T-cells, and T-cells—that have been stimulated in vitro with interleukin 2 (IL‑2)[1][3]. These effector immune cells acquire the ability to lyse a broad range of tumor targets, including those resistant to classical NK-cell activity. LAK cell therapy was developed as an early form of adoptive immunotherapy for cancer; it involves culturing peripheral blood lymphocytes from patients with IL‑2 to generate these highly cytotoxic effectors before reinfusion into the patient[1][10]. The mechanism is distinct from that of unmodified NK or T-cells because LAK cells can kill both autologous and allogeneic tumor targets without major histocompatibility complex restriction[4]. LAK "cells" are not themselves a druggable protein or gene product but rather an **ex vivo manipulated cellular product**. Therefore, they do not fit standard definitions for therapeutic molecular targets such as receptors or enzymes. The term is sometimes misapplied as if referring to a single molecule; in reality, it refers collectively to the functional state induced in certain immune effector populations by cytokines like IL‑2. Because "lymphokine‑activated killer cell" does not refer to a specific molecule or receptor but instead describes an activated cellular phenotype used therapeutically in cancer immunotherapy research and clinical trials—primarily via ex vivo expansion using IL‑2—the entry should be flagged as incorrect for use as a canonical molecular target name[1][10].

Other names

LAK celllymphokine activated killer celllymphokine-activated killer cells (plural)

Activation by interleukin 2 induces cytotoxic activity against tumor cells resistant to natural killer (NK) cells[1][2][3].